Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Strahlentherapie und Onkologie
Published in: Strahlentherapie und Onkologie 11/2014

01-10-2014 | Literatur kommentiert

Strahlentherapie (4 Gy vs. 24 Gy) von Patienten mit indolentem Non-Hodgkin-Lymphom

Ergebnisse der FORT-Studie

Authors: Prof. Dr. Klaus Herfarth, Laila König

Published in: Strahlentherapie und Onkologie | Issue 11/2014

Login to get access

Auszug

Hoskin PJ, Kirkwood AA, Popova B et al (2014) 4 Gy versus 24 Gy radiotherapy for patients with indolent lymphoma (FORT): a randomised phase 3 non-inferiority trial. Lancet Oncol. 15(4):457–463 …
Literature
1.
Lowry L, Smith P, Qian W et al (2011) Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial. Radiother Oncol 100:86–92PubMedCrossRef
2.
Ganem G, Lambin P, Socie G et al (1994) Potential role for low dose limited-field radiation therapy (2 × 2 grays) in advanced low-grade non-Hodgkin’s lymphomas. Hematol Oncol 12:1–8PubMedCrossRef
3.
Haas RL, Poortmans P, de Jong D et al (2003) High response rates and lasting remissions after low-dose involved field radiotherapy in indolent lymphomas. J Clin Oncol 21:2474–2480PubMedCrossRef
4.
5.
Fasola CE, Jones JC, Huang DD, Le QT, Hoppe RT, Donaldson SS (2013) Low-dose radiation therapy (2 Gy × 2) in the treatment of orbital lymphoma. Int J Radiat Oncol Biol Phys 86:930–935PubMedCrossRef
6.
Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216PubMedCrossRef
7.
Cheson BD, Horning SJ, Coiffier B et al (1999) Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17:1244PubMed
8.
Skvortsova I, Popper BA, Skvortsov S et al (2005) Pretreatment with rituximab enhances radiosensitivity of non-Hodgkin’s lymphoma cells. J Radiat Res 46:241–248PubMedCrossRef
Metadata
Title
Strahlentherapie (4 Gy vs. 24 Gy) von Patienten mit indolentem Non-Hodgkin-Lymphom
Ergebnisse der FORT-Studie
Authors
Prof. Dr. Klaus Herfarth
Laila König
Publication date
01-10-2014
Publisher
Springer Berlin Heidelberg
Published in
Strahlentherapie und Onkologie / Issue 11/2014
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI
https://doi.org/10.1007/s00066-014-0728-8

Other articles of this Issue 11/2014

Strahlentherapie und Onkologie 11/2014 Go to the issue

Original article

In vivo dosimetry in intraoperative electron radiotherapy

Letter to the Editor

Cutis verticis gyrata-like skin toxicity during treatment of melanoma patients with the BRAF inhibitor vemurafenib after whole-brain radiotherapy is a consequence of the development of multiple follicular cysts and milia

Original article

Evaluation of the prognostic role of tumor cell podoplanin expression in locally advanced squamous cell carcinoma of the head and neck

Original article

Commissioning and first clinical application of mARC treatment

Original article

New possibilities for volumetric-modulated arc therapy using the AgilityTM 160-leaf multileaf collimator

Original article

Simultaneous integrated boost intensity-modulated radiotherapy in esophageal carcinoma